Merck KGaA has swooped into a neurological-focused pact with RNA biotech Skyhawk Therapeutics that could top out at $2 ...

Privately-held US biotech Skyhawk Therapeutics has announced a strategic research collaboration with Germany’s Merck KGaA ...

Skyhawk's RNA tech could be Merck's next blockbuster play as drug setbacks and looming patent cliffs force a reinvention.

Merck KGaA agreed to collaborate with Skyhawk Therapeutics Inc. to develop neurological therapies in a deal that could be ...

Waltham, Massachusetts–based Skyhawk Therapeutics has been collecting collaborations with larger companies in spades since ...

Skyhawk recently started dosing patients in its phase 2/3 FALCON-HD trial of lead candidate SKY-0515, involving patients with ...

Under the deal, Skyhawk was in line for around $600 million per program target, which came in the form of an undisclosed upfront cash payment and, if Merck exercises its option, potential opt-in ...

Adding another name to an impressive roster of partners assembled over the past few years, Skyhawk Therapeutics Inc. inked a neurology-focused deal with Merck KGaA aimed at discovering small-molecule ...

Skyhawk will receive an upfront cash payment and, to the extent Merck exercises its option, potential milestone payments and royalties on sales of approved products resulting from the collaboration.

Merck & Co. and Skyhawk Therapeutics launch a collaboration that could pay the Waltham, MA, biotech approximately $600 million for every small molecule program the companies develop against ...

Skyhawk Therapeutics enters into an option agreement to grant Merck exclusive global rights to drug candidates pursued under the collaboration upon option exercise Total deal value exceeds ...

Skyhawk announced Monday that will earn up to $600 million in upfront and potential milestone payments for each molecule it develops for pharmaceutical giant Merck & Co. (NYSE: MRK).